Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
ANECTINE (succinylcholine chloride) is a depolarizing neuromuscular blocking agent administered by injection used primarily as an adjunct to anesthesia to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery. It works by binding to acetylcholine receptors at the neuromuscular junction, causing depolarization and subsequent muscle paralysis. This agent has been a standard perioperative medication for over 70 years.
LOE approaching signals transition from maintenance to defensive strategy; commercial teams are likely consolidating to protect revenue against generic/alternative entrants.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on ANECTINE in 2024+ is a defensive, niche career opportunity focused on margin protection and legacy product management rather than growth or innovation. Roles emphasize field presence in hospitals/ASCs, safety monitoring given adverse event profile, and generic/competitive mitigation.
Worked on ANECTINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.